News From CanRIO

A new article published by CanRIO members in ACR Open Rheumatology (February 18, 2025) suggests that ICI related inflammatory arthritis (IA) frequently persists after ICI discontinuation. Chronic ICI-IA is associated with improved progression free survival, but not overall survival, as compared to acute ICI-IA. See link for details:… Read More

Congratulations to Dr. Marie Hudson who has been awarded a Arthritis Society of Canada grant to study the mechanisms underlying rheumatic immune related adverse events! Using a large bank of tissue samples from people with cancer who were treated with immune checkpoint inhibitors, Dr. Hudson’s team will compare these cell… Read More

Congratulations to Dr. Shahin Jamal and Dr. Tom Appleton on receiving a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant from the Canadian Rheumatology Association Foundation (CRAF)! They are leading the study on Early Adalimumab Induction for Treatment of Steroid-Dependent Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical… Read More

We are pleased to share our new Twitter account! @CanRIO_Tweets Keep connected and updated with news, research, initiatives, and collaborations! Check out the link below. https://twitter.com/CanRIO_Tweets… Read More

CanRIO is thrilled to launch the first educational website dedicated to the rheumatic complications of immunotherapy. We hope that this website will serve as an educational resource to rheumatologists, oncologists and all healthcare providers who care for cancer patients receiving immunotherapy. Read More

CanRIO has just published its second national case series. This retrospective cohort study included 27 patients with pre-existing autoimmune disease (PAD) treated with immunotherapy. Consistent with previously published studies, PAD exacerbations were common, however generally mild and manageable. Compared to our Canadian cohort without PAD, there were higher rates of… Read More